Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
X
Share Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts

Investor Overview

Corporate Profile
vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.
Presentations
DateTitle
06/15/17
Download Documentation Investor Presentation
07/27/16
Download Documentation AAIC 2016 Azeliragon Presentation
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
07/13/17vTv Therapeutics to Present Two Posters at the 2017 Alzheimer's Association International Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Jul. 13, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that data on the company’s phase 3 Alzheimer’s candidate, azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE), will be presented at the 2017 Alzheimer's Association International Conference (AAIC) held in London, England, July 16 – 20, 2017. Details of the poster presentations are listed below: ... 
Printer Friendly Version
06/11/17vTv Therapeutics Presents Data Highlighting Further Potential of TTP273 at American Diabetes Association 77th Scientific Sessions
Lower doses of TTP273 may demonstrate a more pronounced reduction in HbA1c and other key endpoints HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 11, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced that results from a Phase 2 clinical study of TTP273, an investigational, oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of Type 2 diabetes, were presented at the American Diabetes Association 77th Scientific Sessio... 
Printer Friendly Version
06/08/17vTv Therapeutics to Present Two Posters at the American Diabetes Association’s 77th Scientific Sessions
HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 8, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that Company management will present two posters featuring vTv Therapeutics’ orally administered, non-peptide GLP-1R agonist at the American Diabetes Association’s... 
Printer Friendly Version
06/01/17vTv Therapeutics Completes Enrollment of Part B of Pivotal Phase III STEADFAST Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease
-- Azeliragon is the only RAGE receptor antagonist in clinical development for Alzheimer’s Disease -- HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 1, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced the completion of enrollment for vTv’s Phase 3 placebo-controlled trial, STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to Symptomatic Therapy). STEADFAST is evaluating the efficacy and safety of azeliragon, a... 
Printer Friendly Version
Webcasts
There are currently no items available.
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.